SRPTHIGH SIGNALFINANCIAL10-K

SRPT experienced massive financial deterioration with net losses increasing over 1,300% to -$713.4M despite revenue growing 450% to $2.2B, indicating severe operational inefficiencies or one-time charges.

The dramatic disconnect between revenue growth and profitability collapse suggests either major one-time impairments, acquisition-related costs, or fundamental operational problems that are destroying shareholder value. The company's debt increased 490% while cash declined 27%, creating potential liquidity concerns and indicating aggressive financing to fund operations or acquisitions.

Comparing 2026-03-02 vs 2025-02-28View on EDGAR →
FINANCIAL ANALYSIS

SRPT shows a paradoxical financial profile with revenue surging 450% to $2.2B while simultaneously posting catastrophic losses of -$713.4M (a 1,310% deterioration) and negative gross profit of -$29.1M, suggesting either major acquisition costs, impairments, or severe operational dysfunction. The balance sheet deteriorated significantly with debt increasing 490% to $829M and cash declining 27% to $801.3M, while the swing from $218.1M operating income to -$699.8M operating loss indicates fundamental business model stress. This combination of explosive revenue growth paired with even more explosive loss generation, rising debt, and declining cash creates serious questions about the sustainability and quality of the company's financial position.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
-2107.4%
$1.9M→-$38.1M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Net Income
P&L
-1310.8%
-$50.6M→-$713.4M

Net income declined 1310.8% — review whether driven by operations, interest costs, or non-recurring items.

Total Debt
Balance Sheet
+490%
$140.5M→$829.0M

Debt increased 490% — substantial leverage increase; assess whether deployed for growth or covering losses.

Revenue
P&L
+450.4%
$399.4M→$2.2B

Strong top-line growth of 450.4% — accelerating demand or successful expansion into new markets.

Operating Income
P&L
-420.9%
$218.1M→-$699.8M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Gross Profit
P&L
-113.3%
$219.3M→-$29.1M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Current Liabilities
Balance Sheet
+49.7%
$731.7M→$1.1B

Current liabilities surged 49.7% — significant near-term obligations; verify ability to meet short-term debt.

Accounts Receivable
Balance Sheet
-33.8%
$602.0M→$398.2M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Cash & Equivalents
Balance Sheet
-27.4%
$1.1B→$801.3M

Cash decreased 27.4% — monitor burn rate and upcoming capital needs.

Capital Expenditure
Cash Flow
-25.5%
$137.0M→$102.0M

Capex reduced 25.5% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

LANGUAGE CHANGES
NEW — 2026-03-02
PRIOR — 2025-02-28
ADDED
Even though certain of our products have received accelerated approval from the FDA, they face future post-approval development and regulatory requirements, which present additional challenges for us to successfully navigate.
Failure to obtain or maintain regulatory exclusivity for our products could result in our inability to protect our products from competition and our business may be adversely impacted, If there are significant delays in obtaining, or if we are unable to obtain or maintain required regulatory approvals, we will not be able to commercialize our product candidates in a timely manner or at all.
Historical revenues from eteplirsen, golodirsen and casimersen through our EAP outside the U.S.
Our products or product candidates may cause undesirable side effects, result in new safety signals or have other properties that could delay or prevent regulatory approval of product candidates, limit the commercial potential or result in significant negative consequences (including revocation) following any existing or potential marketing approval.
Our announced strategic restructuring plan may not result in anticipated reductions in our annual combined research and development and selling, general and administrative expenses and may disrupt our business in unexpected ways.
+7 more — sign up free →
REMOVED
Even though EXONDYS 51, VYONDYS 53, AMONDYS 45 and ELEVIDYS (with respect to non-ambulatory patients) have received accelerated approval from the FDA, they face future post-approval development and regulatory requirements, which present additional challenges for us to successfully navigate.
Failure to obtain or maintain regulatory exclusivity for our products could result in our inability to protect our products from competition and our business may be adversely impacted.
Historical revenues from eteplirsen, golodirsen and casimersen through our early access program ( EAP ) outside the U.S.
Hoffman-La Roche Ltd ( Roche ) and our collaboration and license agreement with Arrowhead Pharmaceuticals, Inc.
( Arrowhead ), and may seek or engage in future collaborations, strategic alliances, acquisitions or licensing agreements that complement or expand our business.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →